Bristol Myers Squibb (BMS; NYSE: BMY) has announced results from three distinct clinical trials assessing the efficacy of its CAR-T therapy Breyanzi (lisocabtagene maraleucel) in treating patients with relapsed or refractory large B-cell lymphoma (LBCL), mantle cell lymphoma (MCL), and relapsed or refractory follicular lymphoma (FL).
In a placebo-controlled, late-stage study involving LBCL patients, Breyanzi demonstrated a significant improvement in event-free survival (EFS), increasing from 2.4 to 29.5 months. Additionally, the treatment elevated overall and complete response rates from 49% to 87% and from 43% to 74%, respectively.
Phase I data from the MCL trial indicated that Breyanzi exhibited comparable efficacy across various patient subgroups categorized by prior lines of therapy and response to previous BTK inhibitors, with the most notable benefits seen in patients who had received 2-4 prior lines of therapy.
Lastly, an intermediate-stage trial in patients with FL showed consistent response rates to Breyanzi, irrespective of bridging therapy status.- Flcube.com
